Key factors
sym | NVO |
exch | US |
MCap | 550.36B |
Beta | 0.195 |
PE Ratio | 46.32 |
EPS | 2.65 |
Div | 9.4 |
Div Yld | 1.119 |
Div date | 2024-03-22 |
Yesterday
sym | NVO |
exch | US |
close | 128.64 |
50 Day MA | 126.06 |
200 Day MA | 103.57 |
52 Week High | 137.57 |
52 Week Low | 74.91 |
Target Price | 143.37 |
Market Cap Mln | 550.36K |
Share statistics
Shares Outstanding | 4.461B |
Shares Float | 3.192B |
Percent Institutions | 9.297 |
PercentInsiders | 0.004 |
SharesShort | 2833.29K |
Short Ratio | 0.5 |
Shares Short Prior Month | 4884.03K |
Short Percent | 0.139 |
Short Percent Float | 0.139 |
Income
Revenue TTM | 232.26B |
Revenue Per Share TTM | 51.81 |
Quarterly Revenue Growth YOY | 37.00 |
Gross Profit TTM | 148.50B |
EBITDA | 109.81B |
Diluted Eps TTM | 2.65 |
Quarterly Earnings Growth YOY | 63.09 |
earning
Operating Margin TTM | 0.427 |
PEGRatio | 2.399 |
Trailing PE | 46.32 |
EPS Estimate Current Quarter | 0.65 |
EPS Estimate Current Year | 3.33 |
EPS Estimate Next Quarter | 0.81 |
EPS Estimate Next Year | 3.99 |
Earnings Share | 2.65 |
Dividend
Forward Annual Dividend Rate | 1.37 |
Forward Annual Dividend Yield | 1.119 |
Payout Ratio | 2.270 |
Dividend Date | 2024-04-02 |
Last Split Date | 2023-09-20 |
Last Split Factor | 2:1 |
business
Enterprise Value Ebitda | 4.921 |
Enterprise Value Revenue | 2.428 |
Book Value /share | 23.90 |
Price Book MRQ | 36.20 |
Price Sales TTM | 2.430 |
ProfitMargin | 0.360 |
ReturnOnAssetsTTM | 0.233 |
ReturnOnEquityTTM | 0.880 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Pharmaceuticals |
Gic Sector | Health Care |
Gic Sub Industry | Pharmaceuticals |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US6701002056 |
Code | NVO |
CUSIP | 670100205 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NYSE |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | ADR |
info
Fiscal Year End | December |
ForwardPE | 37.59 |
Full Time Employees | 63370 |
IPODate | 1982-01-04 |
International Domestic | International Domestic |
MostRecent Quarter | 2023-12-31 |
Contact
Name | Novo Nordisk A/S |
Address | Novo Alle 1, Bagsvaerd, Denmark, 2880 |
Country Name | USA |
Phone | 45 44 44 88 88 |
Web URL | https://www.novonordisk.com |
Logo URL | /img/logos/US/NVO.png |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.